Côd QR

First Report of Response to Tarlatamab in a Patient With DLL3-Positive Pulmonary Carcinoid: Case Report

Tarlatamab, a DLL3-targeting bispecific T-cell engager, has rapidly assumed the role of a new standard of care in the later-line treatment of extensive-stage SCLC. Little is known about the efficacy of tarlatamab in other histologies such as DLL3-expressing metastatic pulmonary carcinoid tumor, a cl...

Disgrifiad llawn

Wedi'i Gadw mewn:
Prif Awduron: Alissa J. Cooper, MD, Natasha Rekhtman, MD, PhD, Marina K. Baine, MD, PhD, Marie C. Thomas, DNP, FNP-C, Alia C. Lynch, PharmD, BCOP, Ryan D. Gentzler, MD, MS
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Elsevier 2024-12-01
Cyfres:JTO Clinical and Research Reports
Pynciau:
Carcinoid
Neuroendocrine
Tarlatamab
Case report
Mynediad Ar-lein:http://www.sciencedirect.com/science/article/pii/S2666364324001206
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg